{
    "organizations": [],
    "uuid": "ec12b51a94dea982eef6618fa391477e58439bd2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-meridian-bioscience-reports-q1-gaa/brief-meridian-bioscience-reports-q1-gaap-eps-of-0-15-idUSASB0C2B8",
    "ord_in_thread": 0,
    "title": "BRIEF-Meridian Bioscience Reports Q1 GAAP EPS Of $0.15",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 25 (Reuters) - Meridian Bioscience Inc:\n* MERIDIAN BIOSCIENCE REPORTS FIRST QUARTER 2018 OPERATING RESULTS, DECLARES REGULAR FIRST QUARTER CASH DIVIDEND, AND REAFFIRMS FISCAL 2018 GUIDANCE\n* Q1 NON-GAAP EARNINGS PER SHARE $0.15 * Q1 GAAP EARNINGS PER SHARE $0.15 * Q1 REVENUE $52.3 MILLION VERSUS I/B/E/S VIEW $49 MILLION * Q1 EARNINGS PER SHARE VIEW $0.15 -- THOMSON REUTERS I/B/E/S\n* REAFFIRMS FY 2018 NON-GAAP EARNINGS PER SHARE VIEW $0.65 TO $0.68\n* REAFFIRMS FY 2018 GAAP EARNINGS PER SHARE VIEW $0.59 TO $0.62\n* SEES FY 2018 REVENUE $207 MILLION TO $212 MILLION * ‍CONTINUING TO WORK WITH FDA REGARDING USE OF VENOUS BLOOD WITH MAGELLAN‘S LEADCARE TESTING SYSTEMS​\n* ‍MAGELLAN LEAD TESTING BUSINESS UNIT REVENUES DECLINED BY 20% IN QUARTER YEAR-OVER-YEAR​\n* ‍ANTICIPATE A REBOUND IN MAGELLAN BUSINESS IN Q2 AND A RETURN TO GROWTH FOR QUARTER​\n* ‍ILLUMIGENE CMV, FIRST MOLECULAR TEST FOR CYTOMEGALOVIRUS, IS TARGETED TO LAUNCH LATE IN CALENDAR YEAR 2018​\n* ‍BUSINESS OUTLOOK FOR FISCAL 2018 REMAINS UNCHANGED​ * FY2018 EARNINGS PER SHARE VIEW $0.66, REVENUE VIEW $207.1 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-25T20:25:00.000+02:00",
    "crawled": "2018-01-26T21:25:52.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "meridian",
        "bioscience",
        "inc",
        "meridian",
        "bioscience",
        "report",
        "first",
        "quarter",
        "operating",
        "result",
        "declares",
        "regular",
        "first",
        "quarter",
        "cash",
        "dividend",
        "reaffirms",
        "fiscal",
        "guidance",
        "q1",
        "earnings",
        "per",
        "share",
        "q1",
        "gaap",
        "earnings",
        "per",
        "share",
        "q1",
        "revenue",
        "million",
        "versus",
        "view",
        "million",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "reaffirms",
        "fy",
        "earnings",
        "per",
        "share",
        "view",
        "reaffirms",
        "fy",
        "gaap",
        "earnings",
        "per",
        "share",
        "view",
        "see",
        "fy",
        "revenue",
        "million",
        "million",
        "work",
        "fda",
        "regarding",
        "use",
        "venous",
        "blood",
        "magellan",
        "leadcare",
        "testing",
        "lead",
        "testing",
        "business",
        "unit",
        "revenue",
        "declined",
        "quarter",
        "rebound",
        "magellan",
        "business",
        "q2",
        "return",
        "growth",
        "cmv",
        "first",
        "molecular",
        "test",
        "cytomegalovirus",
        "targeted",
        "launch",
        "late",
        "calendar",
        "year",
        "outlook",
        "fiscal",
        "remains",
        "fy2018",
        "earnings",
        "per",
        "share",
        "view",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}